The ongoing Mpox outbreak, which has seen over 17,000 cases reported in Africa, underscores the urgent need for vaccines and diagnostic tools to control the spread of the disease. With India’s strong history in vaccine production and its growing biotechnology sector, the current health crisis presents a critical opportunity for India to contribute to global health security and bolster its own health infrastructure. India’s recent policy move, the Biotechnology for Economy, Environment, and Employment (BioE3), positions the country to meet this challenge by expanding vaccine production capabilities.
Global Health Crisis: The Mpox Outbreak
Mpox, formerly known as Monkeypox, has spread across various continents, affecting both children and adults, with the Democratic Republic of Congo (DRC) being the most impacted. The disease has raised alarm due to the rise in severe cases and mortality, particularly in vulnerable populations like children, malnourished individuals, pregnant women, and the immune-compromised. Current data suggest that the disease has multiple strains with varying severity, and as the global number of cases grows, there is an increasing demand for vaccines.
The World Health Organization (WHO) declared Mpox a Public Health Emergency of International Concern (PHEIC), emphasizing the importance of urgent action. In response, countries such as the United States and the European Union have pledged to supply vaccines, but the available doses are insufficient to meet the demands. The situation highlights the pressing need for increased vaccine production, particularly for countries in Africa, which are facing both a shortage of vaccines and diagnostic tools.
India’s Role in Vaccine Production
India, with its well-established pharmaceutical and biotechnology sectors, has the potential to take a leading role in addressing the Mpox vaccine shortage. The Serum Institute of India (SII) and Bharat Biotech, two of India’s largest vaccine manufacturers, have already shown their capability by producing vaccines for COVID-19 and malaria. These companies are poised to replicate their success with Mpox vaccines, ensuring that India not only meets domestic health security needs but also plays a significant role in global health diplomacy.
Challenges and Strategic Solutions
Despite the potential, several challenges need to be addressed. The limited supply of Mpox vaccines and diagnostics, combined with the urgency of the outbreak, calls for a collaborative global effort. India has made strides by approving domestically developed Mpox diagnostic kits, which could aid in early detection and better management of the disease in high-risk regions. To scale up vaccine production, India must leverage public-private partnerships and global collaborations, ensuring equitable access to vaccines for vulnerable populations in Africa.
Moreover, India’s vaccine production capacity needs to be aligned with global health priorities, ensuring that vaccines are distributed effectively and reach the regions most in need. This requires a robust supply chain, technology transfer agreements, and the involvement of international health organizations like the WHO and UNICEF.
Conclusion
The Mpox outbreak presents both a challenge and an opportunity for India to contribute to global health security. Through its BioE3 policy and its well-established vaccine manufacturing capabilities, India is positioned to play a leading role in addressing the vaccine shortage and supporting global health efforts. Know more about the issue in a detailed article here.
